secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001641172-25-002514
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 5.08, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics raises up to $7.3M in private placement; resets annual meeting to June 2
--------------------------------------------------------------------------------

- Initial closing on April 2: sold 9.93M shares and 509,736 pre-funded warrants for $1.1M.
- Second closing of $6.2M (48.33M shares, 10.54M warrants) subject to stockholder approval by June 30 (or July 30 if SEC reviews).
- Purchase price $0.1046 per share; pre-funded warrants at $0.0996 with $0.005 exercise price.
- Investors include existing 32% holder Charles Cherington and former director Nicholas Singer.
- 2025 annual meeting moved to June 2; stockholder proposal deadline is April 13.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000164117225002514/0001641172-25-002514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000164117225002514/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-002514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer